GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,590.00
Bid: 12,590.00
Ask: 12,596.00
Change: 74.00 (0.59%)
Spread: 6.00 (0.048%)
Open: 12,566.00
High: 12,632.00
Low: 12,512.00
Prev. Close: 12,516.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Namibia to start destroying expired vaccines due to slow uptake

Thu, 25th Nov 2021 12:12

By Nyasha Nyaungwa

WINDHOEK, Nov 25 (Reuters) - Namibia has warned that more
than 268,000 doses of AstraZeneca and Pfizer
COVID-19 vaccines are at risk of being destroyed, some as early
as next week, due to a slow uptake by citizens.

Ben Nangombe, executive director in the health ministry,
told Reuters on Thursday that 52,261 AstraZeneca vaccines will
expire on Tuesday next week, while 215,996 Pfizer shots will be
destroyed in January and February if they find no takers as
vaccine hesitancy rises.

Namibia, which has started vaccinating 12- to 17-year olds
with the Pfizer vaccine after the WHO said on Nov. 15 that it is
suitable for people in that age group, has 809,414 doses
available nationally.

The southern African nation recorded 15 new cases on Tuesday
to bring the number of active cases to 85 compared to a peak of
2,547 cases in a single day on June 24.

Only 298,503, or 20% of an estimated eligible population of
1.5 million, have been fully vaccinated in Namibia, with the
Chinese-made Sinopharm vaccine the most used after 145,483
people received two doses since the country’s vaccination
programme started in March.

The Russian-made Sputnik V vaccine has been used the least,
with only 71 people fully vaccinated before its rollout was
suspended on Oct. 23, days after the drugs regulator in
neighbouring South Africa flagged concerns about its safety for
people at risk of HIV.

South African health regulator SAHPRA decided against
approving an emergency use application for Sputnik V after some
studies suggested vaccines using the Adenovirus Type 5 vector -
which Sputnik V does - can lead to higher susceptibility to HIV
in men.

South Africa and Namibia have high HIV prevalence rates.
(Reporting by Nyasha Nyaungwa; editing by Wendell Roelf and
Giles Elgood)

More News
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:48

LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials

(Alliance News) - Stock prices in London opened in the green on Wednesday, as hopes for US interest rate cuts in the new year continued to propel global equities higher.

Read more
27 Dec 2023 08:26

London open: FTSE takes cues from Wall Street 'Santa rally'

(Sharecast News) - London's stocks returned from the Christmas break in the green on Wednesday, boosted by a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:24

TOP NEWS: AstraZeneca buys Gracell to "enrich" cell therapy pipeline

(Alliance News) - AstraZeneca PLC on Tuesday said it has agreed to acquire Gracell Biotechnologies Inc, paying about USD1.2 billion for the clinical-stage company.

Read more
27 Dec 2023 07:52

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

Read more
27 Dec 2023 07:02

AstraZeneca to buy Gracell Technologies for $1.2bn

(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.

Read more
26 Dec 2023 21:26

Wall Street ends higher in final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
26 Dec 2023 21:00

Wall Street ends higher in final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
26 Dec 2023 19:41

Wall Street gains on final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
22 Dec 2023 08:47

AstraZeneca, Ionis get US FDA nod for Wainua in "important milestone"

(Alliance News) - AstraZeneca PLC and Ionis Pharmaceuticals Inc on Friday celebrated the news that their drug eplontersen was approved by the US Food & Drug Administration.

Read more
22 Dec 2023 07:50

LONDON BRIEFING: UK on brink of recession as economy contracts in Q3

(Alliance News) - Stocks in London are likely to open lower on Friday, with investors feeling frosty ahead of a US inflation print this afternoon, amid sobering UK economic growth data.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.